Edition:
United States

MannKind Corp (MNKD.OQ)

MNKD.OQ on NASDAQ Stock Exchange Global Market

0.65USD
9 Dec 2016
Change (% chg)

$-0.00 (-0.09%)
Prev Close
$0.65
Open
$0.65
Day's High
$0.67
Day's Low
$0.63
Volume
614,378
Avg. Vol
717,054
52-wk High
$2.24
52-wk Low
$0.41

Summary

Name Age Since Current Position

Kent Kresa

78 2016 Chairman of the Board

Matthew Pfeffer

58 2016 Chief Executive Officer, Chief Financial Officer, Director

Rose Alinaya

54 2016 Senior Vice President, Principal Accounting Officer

Linda Adreveno

60 2015 Senior Vice President - Human Resources

Joseph Kocinsky

52 2015 Chief Technology Officer, Corporate Vice President

David Thomson

49 2002 Corporate Vice President, General Counsel, Corporate Secretary

Michael Castagna

39 2016 Corporate Vice President, Chief Commercial Officer

Raymond Urbanski

57 2015 Corporate Vice President, Chief Medical Officer

James Shannon

59 2015 Director

Ronald Consiglio

72 2003 Independent Director

Michael Friedman

72 2003 Independent Director

David Maccallum

78 2004 Independent Director

Henry Nordhoff

74 2005 Independent Director

Biographies

Name Description

Kent Kresa

Mr. Kent Kresa has been appointed Chairman of the Board at Mannkind Corporation effective February 18, 2016. Until this date, he served as Lead Independent Director at the Company from 2012. Prior to that, he served as Independent Director at the Company from June 2004. His work experience includes the following roles: Chairman Emeritus of Northrop Grumman Corporation, Chairman at Northrop Grumman Corporation (1990-October 2003), Chief Executive Officer at Northrop Grumman Corporation (January 1990- March 2003), President at Northrop Grumman Corporation (from 1987-September 2001), Director at General Motors Company (2003-August 2010), Director at Avery Dennison Corporation (December 2005-April 2010), Member of the Caltech Board of Trustees (from 1994), Board member at Fluor Corporation (from 2003) and Board member at several non-profit organizations and universities. He holds a Bachelor of Science degree and a Master of Science degree in Aeronautics and Astronautics, from Massachusetts Institute of Technology (MIT). He is a member of E.A.A. (Experimental Aircraft Association).

Matthew Pfeffer

Mr. Matthew Jonathan Pfeffer has been appointed Chief Executive Officer, Chief Financial Officer and Director at MannKind Corporation effective January 10, 2016. Until this date, he served as Chief Financial Officer, Vice President and IR Contact Officer at the Company from April 21, 2008. His work experience includes the following roles: Chief Financial Officer and Senior Vice President of Finance and Administration of VaxGen, Inc. (March 200-April 2008), Chief Financial Officer of Cell Genesys, Inc. (from 1998), Employee at Price Waterhouse. He holds a Bachelors degree in Accounting from the University of California, Berkeley and is a Certified Public Accountant.

Rose Alinaya

Ms. Rose Alinaya serves as Senior Vice President, Principal Accounting Officer of Mannkind Corporation, effective January 12, 2016. Until this date, she served as Vice President - Finance at the Company from March 2011 and prior to that as Controller at the Company from June 2003. She holds a Bachelor of Science degree in Accounting Information Systems from California State University, Northridge. She is a Certified Public Accountant.

Linda Adreveno

Ms. Linda Adreveno serves as Senior Vice President - Human Resources of the Company. Ms. Adreveno has been our Senior Vice President of Human Resources since March 2015. Prior to joining us, she was President of reOptimize, Inc., a boutique Human Resources consulting firm working with small to medium sized companies, from April 2006 to March 201, and Senior Director of Human Resources at Nektar Therapeutics from August 2001 to January 2006. Previously, she held senior management positions at Scient, a consulting company, and Sybase. She is a member of the Society of Human Resources Management (SHRM) and is also a certified Senior Professional in Human Resources (SPHR). She holds a bachelor’s degree in liberal arts from Regents College (now Excelsior College) in New York, and a master’s degree in management from John F. Kennedy University in California.

Joseph Kocinsky

Mr. Joseph Kocinsky serves as Chief Technology Officer, Corporate Vice President of the Company, since October 2015. Mr. Kocinsky has over 28 years of experience in the pharmaceutical industry in technical operations and product development. Prior to joining us in 2003, he held a variety of technical and management positions with increased responsibility at Schering-Plough Corp. Mr. Kocinsky holds a bachelor’s degree in chemical engineering and a master’s degree in Biomedical Engineering from New Jersey Institute of Technology and a master’s degree in business administration from Seton Hall University.

David Thomson

Dr. David B. Thomson, Ph.D., J.D., is Corporate Vice President, General Counsel and Corporate Secretary since January 2002. Prior to joining us, he practiced corporate/commercial and securities law at a major Toronto law firm. Earlier in his career, Dr. Thomson was a post-doctoral fellow at the Rockefeller University. Dr. Thomson obtained his bachelor’s degree, master’s degree and Ph.D. degree from Queens University and obtained his J.D. degree from the University of Toronto.

Michael Castagna

Dr. Michael E. Castagna, Pharm.D., serves as Corporate Vice President, Chief Commercial Officer of Mannkind Corporation. Dr. Castagna, Pharm.D has been our Chief Commercial Officer since March 2016. From November 2012 until he joined MannKind, Dr. Castagna was at Amgen, Inc., where he initially served as Vice President, Global Lifecycle Management and was most recently Vice President, Global Commercial Lead for Amgen’s Biosimilar Business Unit. From 2010 to 2012, he was Executive Director, Immunology, at Bristol-Myers Squibb. Before BMS, Dr. Castagna served as Vice President & Head, Biopharmaceuticals, North America, at Sandoz. He has also held positions with commercial responsibilities at EMD (Merck) Serono, Pharmasset and DuPont Pharmaceuticals. He received his pharmacy degree from University of the Sciences-Philadelphia College of Pharmacy, a Doctor of Pharmacy from Massachusetts College of Pharmacy & Sciences and an MBA from The Wharton School of Business at the University of Pennsylvania.

Raymond Urbanski

Dr. Raymond W. Urbanski, M.D., Ph.D. serves as Corporate Vice President, Chief Medical Officer of the Company. Dr. Urbanski, M.D., Ph.D. has been our Chief Medical Officer since August 2015. Prior to joining us, he served as Chief Medical Officer at Mylan, Inc. from September 2012 to September 2014 and Chief Medical Officer at Metabolex, Inc. from October 2011 to June 2012. From June 2004 to October 2011, Dr. Urbanski held several positions with Pfizer Inc. most recently as Vice President and Medical Head of the Established Products Business Unit. He also served as Vice President of Research and Development and Chief Medical Officer at Suntory Pharmaceutical, Inc. Dr. Urbanski earned both his M.D. and Ph.D. in pharmacology and toxicology at the University of Medicine and Dentistry of New Jersey. He completed his residency and fellowship training at Thomas Jefferson University Hospital in Philadelphia.

James Shannon

Dr. James S. Shannon, M.D., MRCP (UK), is an Director of the Company. He resigned as an Independent Director of MannKind Corporation effective May 1, 2012. He has more than 20 years experience at senior levels of the pharmaceutical industry and until his retirement in 2008 was Global Head of Drug Development for Novartis Pharma AG based in Basel, Switzerland. He entered the pharmaceutical industry in 1987 joining Sterling-Winthrop, Inc., where he held positions of increasing responsibility in the management of Research and Development ultimately serving as Senior Vice-President, Clinical Development. In 1994 he joined Sandoz, which later became Novartis, as Head of Drug Regulatory Affairs, where he held a number of positions including Head of the Integration Office for R&D overseeing the creation of the Novartis R&D groups from those of Ciba and Sandoz and also Head of the Cardiovascular Strategic Team where he oversaw the design and implementation of the clinical trial program for Diovan. Subsequently he was appointed Global Head of Project Management before being appointed Global Head of Clinical Development and Medical Affairs in 1999, a position that he held until 2005 when he was appointed to Head Pharma Development. Currently Dr. Shannon is also a director of Biotie Therapies Corp. and Endocyte, Inc. Dr. Shannon is trained in Medicine and Cardiology and received his undergraduate and postgraduate degrees at Queen’s University of Belfast and is a Member of the Royal College of Physicians (UK).

Ronald Consiglio

Mr. Ronald J. Consiglio is an Independent Director of Mannkind Corporation., since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge. The Board believes that Mr. Consiglio’s knowledge and understanding of accounting and finance, his experience as a board member and executive officer at financial services firms, combined with his business acumen and judgment provide our Board with valuable accounting, financial and operational expertise and leadership skills.

Michael Friedman

Dr. Michael A. Friedman, M.D., is an Independent Director of MannKind Corporation., since December 2003. In 2014, Dr. Friedman completed a decade of service as the President and Chief Executive Officer of the City of Hope National Medical Center. Previously, from September 2001 until April 2003, Dr. Friedman held the position of Senior Vice President of Research and Development, Medical and Public Policy, for Pharmacia Corporation and, from July 1999 until September 2001, was a senior vice president of Searle, a subsidiary of Monsanto Company. From 1995 until June 1999, Dr. Friedman served as Deputy Commissioner for Operations for the Food and Drug Administration, and was Acting Commissioner and Lead Deputy Commissioner from 1997 to 1998. He joined the board of Celgene Corporation in February 2011 and the board of Smith & Nephew plc in April 2013. Dr. Friedman received a bachelor of arts degree, magna cum laude, from Tulane University, New Orleans, Louisiana, and a doctorate in medicine from the University of Texas, Southwestern Medical School. The Board believes Dr. Friedman’s business experience, including his experience as an executive officer at biopharmaceutical companies and a leading clinical and research center specializing in cancer and diabetes, and his service at the Food and Drug Administration, combined with his business acumen and judgment provide our Board with valuable scientific and operational expertise and leadership skills.

David Maccallum

Mr. David H. MacCallum is an Independent Director of MannKind Corporation., since June 2004. Since 2002, Mr. MacCallum has served as the Managing Partner of Outer Islands Capital, a hedge fund specializing in health care investments. From June 1999 until November 2001, he was Global Head of Health Care investment banking for Salomon Smith Barney, part of Citigroup, a financial institution. Prior to joining Salomon Smith Barney, he was Executive Vice President and Head of the Health Care group at ING Barings Furman Selz LLC, an investment banking firm and subsidiary of ING Group, a Dutch financial institution, from April 1998 to June 1999. Prior to that, Mr. MacCallum formed the Life Sciences group at UBS Securities, an investment banking firm, where he was Managing Director and Global Head of Life Sciences from May 1994 to April 1998. Before joining UBS Securities, he built the health care practice at Hambrecht & Quist, an investment banking firm, where he was Head of Health Care and Co-Head of Investment Banking. From 2005 to October 2010, Mr. MacCallum served as a director of Zymogenetics, Inc. From 2002 to 2008, he served as a director of Vital Signs, Inc. Mr. MacCallum received an A.B. degree from Brown University and an M.B.A. degree from New York University. He is a Chartered Financial Analyst. The Board believes that Mr. MacCallum’s knowledge and understanding of accounting and finance, his business experience in the investment banking industry, combined with his business acumen and judgment provide our Board with valuable accounting, financial and operational expertise and leadership skills.

Henry Nordhoff

Mr. Henry L. Nordhoff is an Independent Director of MannKind Corporation., since March 18, 2005. He has served as a director of BioTime, Inc. since June 2013 and as a director of Asterias Biotherapeutics, Inc. since October 2013. Mr. Nordhoff retired as Chairman of the Board of Gen-Probe Incorporated, a clinical diagnostic and blood screening company, at the end of 2011, after serving as its Chairman since September 2002. He also served as Chief Executive Officer and President of Gen-Probe from July 1994 until May 2009. Prior to joining Gen-Probe, he was President and Chief Executive Officer of TargeTech, Inc., a gene therapy company that was merged into Immune Response Corporation. Prior to that, Mr. Nordhoff was at Pfizer, Inc. in senior positions in Brussels, Seoul, Tokyo and New York. He received a B.A. in international relations and political economy from Johns Hopkins University and an M.B.A. from Columbia University. The Board believes that Mr. Nordhoff’s business experience, including his experience as a director and executive officer at pharmaceutical and biotech companies, combined with his business acumen and judgment provide our Board with valuable operational expertise and leadership skills.